GET DAILY SIGNALSCalciMedica (CALC): $10 Price Target and +670% Upside Potential
Key Takeaways
- The central target used here is $10 per share, the arithmetic mean of the two current, attributed analyst price targets reviewed ($9 from Guggenheim and $10 from Oppenheimer), rounded from $9.50.
- At a latest verified price near $1.30, reaching $10 would require roughly 670% upside — an exceptionally large move.
- Coverage is thin and concentrated: only two current Buy-rated targets sit in a narrow $9–$10 range, while H.C. Wainwright downgraded the stock to Hold in January 2026.
- The strongest support comes from clinical progress for lead candidate Auxora in acute pancreatitis and acute kidney injury, not from current financials.
- The biggest risks are a clinical-stage business with no revenue, a modest cash balance, a roughly $9 million market value, and extreme share-price volatility.
Analyst Price Targets and Consensus View
CalciMedica, Inc. (CALC) is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors, led by the intravenous candidate Auxora. As a pre-revenue micro-cap, its sell-side coverage is limited and has shifted materially over the past year.
The most current, attributable targets are Guggenheim's $9 Buy rating, initiated in August 2026, and Oppenheimer's $10 Outperform rating, set in March 2026 when the firm lowered its target from $20. Their mean is $9.50, rounded to $10. Separately, H.C. Wainwright downgraded the stock to Hold in January 2026 and no longer carries an active price target. Some data aggregators still display much higher figures — ranging up to roughly $75 — but those reflect stale targets set when shares traded far above current levels and are not representative of present coverage.
Bullish analysts emphasize the clinical promise of the CRAC-channel platform, while the Hold view reflects caution about near-term catalysts and a depressed valuation for a company still far from commercialization. This is not a broad analyst consensus, but a narrow, high-conviction bull camp set against a more cautious observer. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares traded near $1.30 in November 2026, within a 52-week range of roughly $1.00 to $36.00 and down about 91% over the prior year. A move to $10 would require upside of approximately 670%, a very large move that effectively assumes a re-rating of the entire business rather than a modest incremental gain.
Because CalciMedica generates no product revenue, the path toward any higher valuation depends almost entirely on clinical execution. Positive Phase 2 data for Auxora in acute pancreatitis (the CARPO trial, announced in late 2024) and progress in the KOURAGE Phase 2 acute kidney injury study are the central value drivers. Financing capacity also matters: with roughly $18.6 million in cash and an ongoing net loss, the company will likely need additional capital to advance its pipeline.
Factors That Could Support a Move Toward the Target
- Clinical momentum: Encouraging Phase 2 data for Auxora in acute pancreatitis supports the thesis that CRAC-channel inhibition could address serious conditions with limited treatment options.
- Pipeline breadth: Auxora is also being studied in asparaginase-induced pancreatic toxicity and acute kidney injury, with an oral CRAC inhibitor (CM5480) aimed at chronic inflammatory diseases.
- Analyst conviction: Both current Buy-rated targets imply massive upside from depressed levels, reflecting a view that the market has underpriced the platform's optionality.
- Low base: At a sub-$10 million market capitalization, even modest clinical or financing success could produce a sharp percentage re-rating.
Risks That Could Prevent the Target From Being Reached
- Clinical and regulatory risk: Late-stage trials can fail, and no drug is approved or generating revenue yet.
- Cash runway: A limited balance sheet may force dilutive financings, pressuring the share price further.
- Concentration risk: The company's value rests heavily on a single lead candidate and platform.
- Sentiment and liquidity: As a thinly traded micro-cap, CALC is prone to extreme volatility and sharp drawdowns unrelated to fundamentals.
- Dilution from past financing: The company has repeatedly raised equity at low prices, contributing to the share count and downward pressure.
Technical Levels and Market Structure
The most durable reference points are the 52-week low near $1.00, which acts as a psychological support level, and the 52-week high near $36.00, which illustrates how far the stock has fallen. The $10 target, while ambitious relative to the current price, would still sit well below that prior high. Because the stock has collapsed so sharply, traditional resistance levels are less meaningful than the broader trend, which remains firmly negative until clinical or financing catalysts emerge.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though for a clinical-stage company the effective catalyst timeline can stretch further. The targets reviewed here were issued between March and August 2026 and remain subject to revision. Key items to watch include updates from the KOURAGE acute kidney injury trial, any new data or regulatory feedback on Auxora, quarterly cash balances and financing announcements, analyst rating and target revisions, and broader biotech-sector risk appetite, which strongly influences small-cap valuations.
Using Tickeron’s AI Daily Buy/Sell Signals in Research
In my analysis of names like this, Tickeron’s AI Daily Buy/Sell Signals provide a useful layer for tracking momentum shifts in volatile, low-liquidity stocks. The tool monitors thousands of securities continuously and flags Buy, Sell, or Hold signals based on technical behavior and AI-driven insights, which can complement fundamental reviews when catalysts are still developing.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CALC's RSI Oscillator ascends from oversold territory
The RSI Indicator for CALC moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where CALC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on CALC as a result. In 64 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +16.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CALC advanced for three days, in 185 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CALC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CALC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.684) is normal, around the industry mean (3.498). P/E Ratio (-0.199) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. CALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology